Prevention of respiratory syncytial virus infection in high risk infants: Consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin

Pediatric Infectious Disease Journal

Volumn 15, Issue 12, 1996, Pages 1059-1068

  Meissner, H Cody ^a   Welliver, Robert C ^b   Chartrand, Stephen A ^c   Fulton, David R ^a   Rodriguez, William J A ^d   Groothuis, Jessie R ^e  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e Children's Hospital Colorado   (United States)

Author keywords

hyperimmune globulin; immunoprophylaxis; Respiratory syncytial virus

Indexed keywords

HYPERIMMUNE GLOBULIN; RIBAVIRIN; VIRUS ANTIBODY;

ASEPTIC MENINGITIS; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK ASSESSMENT;

ANIMALS; CLINICAL TRIALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; PROGNOSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RISK FACTORS;

EID: 0030475420     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199612000-00001     Document Type: Review

References (51)

1. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995;8:22-33.
2. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34.
3. Chanock RM, Kim HW, Vargosko AJ, et al. Respiratory Syncytial Virus: I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 1961;176:647-57.
4. Beem M. Repeated infections with respiratory syncytial virus. J Immunol 1967;98:1115-22.
5. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976;134:211-7.
6. Ward KA, Lambden PR, Ogilvie MM, Watt PJ. Antibodies to respiratory syncytial virus polypeptides and their significance in human infection. J Gen Virol 1983;64:1867-76.
7. Glezen WP, Paredes A, Allison JE, Taver LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98:708-15.
8. Groothuis JR, Levin MJ, Rodriguez W, et al. Use of intravenous gamma globulin to passively immunize high-risk children against RSV: safety and pharmacokinetics. Antimicrob Agents Chemother 1991;35:1469-73.
9. Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against RSV disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993;37:1655-8.
10. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
11. The PREVENT Study Group. Reduction of RSV hospitalization among premature infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics (in press).
12. Ventura SJ, Martin JA. Advance report of final natality statistics, 1990. Monthly Vital Stat Rep 1993;41:2-6.
13. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88:527-32.
14. de Sierra TM, Kumar ML, Wasser TE, Murphy BR, Subbarao EK. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr 1993;122:787-91.
15. Hayward AR, Herberger MJ, Groothuis J, Levin MR. Specific immunity after congenital or neonatal infection with cytomegalovirus or herpes simplex virus. J Immunol 1984;133:2469-73.
16. McConnochie KM, Roghmann KJ. Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis. Am J Dis Child 1986;140:806-12.
17. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
18. Simoes EAF, King SJ, Lehr MV, Groothuis JR. Preterm twins and triplets: high-risk group for severe respiratory syncytial virus infection. Am J Dis Child 1993;147:303-6.
19. Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Child 1990;144:346-8.
20. Groothuis JR, Simoes EA, Hemming VG. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSV-IGIV). Pediatrics 1995;95:463-7.
21. Mitchell SC, Kprones SB, Berendes HW. Congenital heart disease in 56 109 births: incidence and natural history. Circulation 1971;43:323-32.
22. Fyler DC, Buckley LP, Hellenbrand WE, et al. Report of the New England Regional Infant Care Program. Pediatrics 1980;65:376-460.
23. Ferency C, Rubin JD, McCarter RJ, et al. Congenital heart disease prevalence at live birth: the Baltimore Washington Infant Study. Am J Epidemiol 1984;121:31-6.
24. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982;307:397-9.
25. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk population of Canadian children. J Pediatr 1992;121:348-54.
26. Anderson LJ, Parker R, Strikas RL. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis 1990;161:650-6.
27. Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995;21:376-9.
28. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987-93.
29. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778-82.
30. Chandwani S, Borkowsky W, Krasinski K, Lawrence R, Welliver R. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr 1990;117:251-4.
31. King JC Jr, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus and noninfected children. Pediatr Infect Dis J 1993;12:733-9.
32. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315:77-81.
33. Madge P, Paton JY, McColl JH, Mackie PK. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 1992;340:1079-83.
34. American Academy of Pediatrics. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infection. Pediatrics 1996;97:137-40.
35. Gruher WC, Wilson SZ, Throop BJ, Wyde PR. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat. Pediatr Res 1987;21:270-4.
36. Whimby E, Champlin RE, England JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for RSV disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16:393-9.
37. Data on file, Medimmune, Inc.
38. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother 1987;31:1882-6.
39. Simoes EAF, Groothuis JR, Tristram DA, et al. RSV-enriched globulin for the prevention of acute otitis media in high risk children. J Pediatr 1996;129:214-9.
40. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
41. Siber GR, Leszczynski J, Pena-Cruz V, et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992;165:456-63.
42. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-50.
43. Bjøro K, Frøland SS, Yun Z, Samdai HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
44. Centers for Disease Control and Prevention. Respiratory syncytial virus and parainfluenza surveillance: United States, 1989-90. MMWR 1990;39:832-9.
45. Welliver RC. Respiratory syncytial virus vaccines. In: Proceedings of the 104th Ross Conference on pediatric research. Strategies for Pediatric Vaccines: Conventional and Molecular Approaches. Columbus, OH: Ross Laboratories Press, 1993:165-72.
46. Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993;122:204-11.
47. American Academy of Pediatrics Committee on Infectious Diseases. Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. Pediatrics 1994;93:682-5.
48. Voter KZ, Henry MM, Stewart PW, Henderson FW. Lower respiratory illness in early childhood and lung function and bronchial reactivity in adolescent males. Am Rev Respir Dis 1988;137:302-7.
49. McConnochie KM, Roghmann KJ. Wheezing at 8 and 13 years: changing importance of bronchiolitis and passive ' smoking. Pediatr Pulmonol 1989;6:138-46.
50. Hay IW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost effectiveness analysis. Am J Managed Care 1996;2:851-61.
51. Heilman CA. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990;161:402-6.